Business
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma
About this update from Adc Therapeutics Sa
[{"type":"text","content":"Company to host corporate webcast to share updated data on December 3, 2025","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"LAUSANNE, Switzerland, Dec. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, December 3, 2025, at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).","length":565,"tagName":"p"},{"type":"image","alt":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","displaySize":"","headline":null,"caption":"ADC Therapeutics logo (PRNewsfoto/ADC Therapeutics SA)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xnw4DzeStakBHZIZhIV_hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","width":400,"height":250}},"href":"https://mma.prnewswire.com/media/2543351/ADC_Therapeutics_SA__logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.","length":486,"tagName":"p"},{"type":"text","content":"About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.","length":298,"tagName":"p"},{"type":"text","content":"ADC Therapeu...